The order includes purchase of PrioClear, a prion capture resin incorporated into Octapharma’s manufacturing process for its solvent/detergent treated plasma product, Octaplas LG.
The resumption of PrioClear supply is likely to begin in the fourth quarter of 2011.
The plasma product is currently approved for marketing in four countries including Germany, Switzerland, Portugal and Australia.